Pipeline

KYNAMRO™ has been approved by the U.S. Food and Drug Administration (FDA)as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Learn More >

An antisense drug that inhibits apoC-III, a protein that is responsible for triglyceride transport in blood. High levels of apoC-III are linked to inflammation, high triglycerides, atherosclerosis and metabolic syndrome. In a Phase 1 study, ISIS-APOCIII_Rx produced significant reductions in apoC-III and triglycerides in healthy volunteers. Learn More >

An antisense drug that inhibits the production of CRP, a protein that is dramatically elevated during inflammatory disorders. Excessive amounts of CRP have been linked to coronary artery disease. In a Phase 1 study, ISIS-CRP_Rx produced statistically significant reductions in CRP in subjects that entered the study with elevated levels of CRP. Learn More >

An antisense drug designed to treat clotting disorders by inhibiting the production of Factor XI, a clotting factor that is produced in the liver. High levels of Factor XI are linked to heart attack, stroke and blood clots. Learn More >

An antisense drug that inhibits the production of apo(a) in the liver and is designed to offer a direct approach to reducing Lp(a), an independent risk factor for cardiovascular disease. High levels of Lp(a) are associated with an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke. Lp(a) promotes premature plaque buildup, or atherosclerosis, in arteries. Learn More >

An antisense drug that inhibits the production of Factor VII, a key component of the tissue factor coagulation pathway, for the treatment or prevention of thrombotic diseases without causing bleeding, which is a common side effect of currently available anti-thrombotic drugs. Learn More >

KYNAMRO™ has been approved by the U.S. Food and Drug Administration (FDA)as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Learn More >

An antisense drug that inhibits the production of ICAM-1, an intracellular adhesion protein that is overexpressed in a wide variety of inflammatory disorders. Our partner, Atlantic Pharmaceuticals, is developing alicaforsen for the treatment of ulcerative colitis and currently supplies alicaforsen in response to physicians’ requests under international Named Patient Supply regulations for patients with IBD.

Learn More >

An antisense drug that inhibits the production of TTR, a carrier protein that transports a thyroid hormone and retinol in the blood. In patients with TTR amyloidosis, both the mutant and normal forms of TTR can build up as fibrils in tissue. ISIS-TTR_Rx inhibits the production of all forms of TTR, offering a unique approach to treating TTR amyloidosis. Learn More >

An antisense drug designed to treat spinal muscular atrophy. SMA occurs from a genetic deletion of a gene responsible for producing a protein critical for normal cellular function. ISIS-SMN_Rx increases the production of this protein by modulating the splicing of a closely related gene, thereby compensating for the underlying genetic defect. Learn More >

An antisense drug that inhibits apoC-III, a protein that is responsible for triglyceride transport in blood. High levels of apoC-III are linked to inflammation, high triglycerides, atherosclerosis and metabolic syndrome. In a Phase 1 study, ISIS-APOCIII_Rx produced significant reductions in apoC-III and triglycerides in healthy volunteers. Learn More >

An antisense drug that inhibits the production of a receptor protein, GHr. GHr reduces the level of a circulating hormone that has been shown to contribute to various diseases. Our partner, Antisense Therapeutics Limited, is developing ATL1103 for the treatment of acromegaly, a disease characterized by abnormal growth of organs, face, hands and feet. Learn More >

An antisense drug that targets the glucocorticoid receptor, or GCCR. Glucocorticoid hormones affect a variety of processes throughout the body, and excessive levels of glucocorticoid hormones can have a detrimental effect on many of the tissues and organs in the body. Learn More >

An antisense drug designed to inhibit the production of AAT in patients with AATD. AATD is a genetic disease that affects 1 out of every 2,500 people in the United States and can lead to severe liver disease, including liver scarring, cirrhosis and liver cancer. ISIS-AAT_Rx should prevent accumulation of misfolded AAT in the liver, thereby offering a unique approach to treat AATD-associated liver disease. Learn More >

Antisense drug designed to prevent hereditary angioedema, or HAE, attacks. ISIS-PKK_Rx inhibits the production of prekallikren, or PKK, a protein produced in the liver that plays an important role in the activation of inflammatory mediators associated with acute attacks of HAE. HAE is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. Learn More >

An antisense drug that inhibits the production of PTP-1B, a protein that negatively regulates insulin receptor signaling. PTP-1B is responsible for turning off the activated insulin receptor, so reducing PTP-1B enhances insulin activity. We have reported positive Phase 2 data showing that antisense inhibition of PTP-1B improved glucose control in patients with type 2 diabetes. Learn More >

An antisense drug designed to inhibit GCCR, a receptor for the hormone, glucacorticoid, that has a variety of effects throughout the body, including promoting liver glucose production and fat storage. Learn More >

An antisense drug designed to inhibit GCGR, a receptor for the hormone, glucagon, that opposes the action of insulin and stimulates the liver to produce glucose. Learn More >

An antisense drug designed to treat obesity by inhibiting the production of FGFR4, a protein that plays an important role in the regulation of fat burning and body weight. Learn More >

An antisense drug that inhibits the production of DGAT2 and is designed to reduce liver fat in patients with nonalcoholic steatohepatitis (NASH), a common and often asymptomatic liver disease that can cause irreversible damage to the liver, and lead to liver cirrhosis and cancer. Learn More >

An antisense drug that inhibits the production of clusterin, a secreted protein that acts as a cell-survival protein and is overexpressed in response to cancer treatments, like chemotherapy, hormone ablation and radiation therapy. Teva and OncoGenex are developing Custirsen (OGX-011) for the treatment of cancer. Custirsin has shown promising results in combination with currently available chemotherapies in several tumor types. Learn More >

An antisense drug that inhibits the production of eIF-4E, a protein that is overexpressed in a variety of cancers. eIF-4E is involved in key growth and survival factors that contribute to tumor progression and the spread of cancer. Learn More >

An antisense drug that inhibits the production of Hsp27, a cell-survival protein that is overexpressed in response to many cancer treatments. Our partner, OncoGenex, is developing OGX-427 for the treatment of a variety of cancers. Learn More >

An antisense drug that inhibits the production of STAT3. STAT3 is a protein involved in the translation of key factors that are critical for tumor cell growth and survival. STAT3 is overactive in a variety of cancers, including ovarian, brain, lung, breast, bone, liver and multiple myeloma. Learn More >

Anantisense drug to an undisclosed target designed to treat cancer. ISIS-AZ1_Rx is the first drug to arise from a research program and enter development under our partnership with AstraZeneca. Learn More >

An antisense drug that inhibits the production of CRP, a protein that is dramatically elevated during inflammatory disorders. Excessive amounts of CRP have been linked to coronary artery disease. In a Phase 1 study, ISIS-CRP_Rx produced statistically significant reductions in CRP in subjects that entered the study with elevated levels of CRP. Learn More >

An antisense drug that inhibits the production of CD49d. CD49d is a subunit of VLA-4 and is involved in a number of inflammatory diseases. Our partner, Antisense Therapeutics Limited, is developing ATL1102 for the treatment of multiple sclerosis. Learn More >

An antisense drug that inhibits the production of the growth factor CTGF. CTGF is overexpressed in damaged skin or tissue following a traumatic event. In 2011, our partner, Excaliard, was acquired by Pfizer. Pfizer is developing EXC 001 for the local treatment of fibrotic diseases, including scarring. In 2011, Excaliard reported data from three Phase 2 studies of EXC 001 demonstrating that treatment with EXC 001 produced statistically significant decreases in scar severity. Learn More >

An antisense drug that inhibits the production of c-raf kinase, a protein associated with the reduction and leakage of new blood vessels in the eye. Our partner, iCo Therapeutics, is developing iCo-007 for the treatment of both diabetic macular edema and diabetic retinopathy. Learn More >

Plazomicin (formerly ACHN-490): An aminoglycoside drug discovered by Achaogen based on technology we licensed to Achaogen. Achaogen is developing plazomicin for the treatment of multi-drug resistant gram-negative bacterial infections. Learn More >

An antisense drug designed to treat anemia of inflammation, the second most common form of anemia associated with a wide variety of conditions, including cancer and inflammatory disorders. XEN701 is the first drug to enter development in Isis’ collaboration with Xenon. Learn More >

An antisense drug to an undisclosed target designed to treat a viral infection. ISIS-GSK3_Rx is the third drug to enter development under our collaboration with GSK. Learn More >